Danaher China Western Innovation Center Begins Operations with First Phase in Science City

Chongqing - To boost the development of Chongqing's biopharmaceutical industry, the first phase of the Danaher China Western Innovation Center, a joint venture with Zein Biotechnology, has officially been implemented in the Western (Chongqing) Science City.

As a global science and technology company, Danaher's third research institute in China, after those in Shanghai and Guangzhou, is focused on advancing cutting-edge biopharmaceuticals and precision medicine applications.

Danaher China Western Innovation Center. (Photo/Danaher)

The Danaher China Western Innovation Center fosters research in spatial genomics, genomics, multi-omics, and clinical pharmacodynamics, with a focus on organoids, cell therapy, and synthetic biology.

The center also supports talent training, innovation incubation, product development, customer service, technical support, and application development, boosting local biopharmaceutical innovation and high-quality production.

Danaher’s subsidiary, Cytiva, a global leader in life sciences, will establish the Cytiva Western Innovation Center in Western (Chongqing) Science City, slated to open in 2025. This center will concentrate on biopharmaceutical process technology development, talent training, and project incubation.

The biopharmaceutical industry is quickly becoming a key part of Western (Chongqing) Science City's "3238" modern manufacturing cluster. Future development will focus on biopharmaceuticals, isotopes, small molecule drugs, medical devices, and digital healthcare.

While attracting top biopharmaceutical companies and advancing as a key hub for life sciences and tech innovation, Science City also depends on high-level innovation platforms like Jinfeng Laboratory. These platforms strongly support industrial development through their innovative capabilities.

Jinfeng Laboratory and the Chinese University of Hong Kong have signed a strategic agreement to focus on pathology biology and stem cell regenerative medicine. This partnership will promote joint research, technology transfer, and cultural exchanges, leading to the establishment of the Chongqing-Hong Kong Life Sciences Center.

A researcher is conducting experiments at the Jinfeng Laboratory. (Photo/Lei Jian)

The laboratory's AI drug design platform has boosted drug screening efficiency and reduced research costs. AI technology has led to breakthroughs in production processes, lowering costs and easing the financial burden on national healthcare and low-income patients.

Jinfeng Laboratory has assembled 40 research teams with over 400 researchers, including five academicians and 33 national-level talents, and a postgraduate ratio exceeding 70%. They have achieved significant outcomes in immunopathology, digital pathology equipment, and AI diagnostics.

The laboratory's research achievements are being translated into practical applications, advancing Chongqing’s goal to become a leading hub for life sciences innovation and fostering a new cluster of precision diagnostics industries.